| General Information of Drug Metabolite (DM) (ID: DM006738) |
| DM Name |
DMXAA acyl glucuronide
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
UDP-glucuronosyltransferase 1A9 (UGT1A9)
|
DME0042
|
| Unclear - Unclear |
ASA-404
|
[1] , [2] |
|
UDP-glucuronosyltransferase 2B7 (UGT2B7)
|
DME0040
|
| Unclear - Unclear |
ASA-404
|
[1] , [2] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| ASA-404 |
DR1664
|
Phase 2 |
Prostate cancer |
|
|
| References |
| 1 |
Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metab Rev. 2002 Nov;34(4):751-90.
|
| 2 |
Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
